-+ 0.00%
-+ 0.00%
-+ 0.00%

Immatics' IMA402 shows 32% confirmed response rate in high-PRAME melanoma patients in Phase 1b trial

PUBT·10/26/2026 11:33:21
Listen to the news
Immatics' IMA402 shows 32% confirmed response rate in high-PRAME melanoma patients in Phase 1b trial
  • Immatics announced updated early-stage trial results showing tumor responses across advanced solid cancers for IMA402 bispecific therapy and IMA203CD8 cell therapy.
  • IMA402 showed durable responses in advanced melanoma with favorable tolerability; results will be presented at the 2026 ESMO meeting.
  • IMA203CD8 results already presented at ESMO showed durable responses across several cancers, including gynecologic tumors, with manageable safety.
  • Development plans include IMA402 combination treatments, with initial lung cancer combination data expected in 2027.
  • A pediatric cancer trial of IMA203CD8 is planned for the first half of 2027, supporting potential use across tumor types.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950103-26-016136), on October 26, 2026, and is solely responsible for the information contained therein.